Heart Failure News and Research

RSS

Heart failure (HF) is a condition in which a problem with the structure or function of the heart impairs its ability to supply sufficient blood flow to meet the body's needs. It should not be confused with cardiac arrest or myocardial infarction.

Bioheart announces primary focus on completing clinical evaluation of cell therapies for heart failure

Bioheart, Inc. announced today that Bioheart's primary focus is on completing clinical evaluation of its cell therapies for treating heart failure and related cardiac diseases.

11 Jan 2011

DAPT shows positive outcomes following treatment with OrbusNeich's Genous Stent

Data from patients who are considered high-risk due to underlying clinical conditions and who cannot be treated with drug eluting stents and the accompanying requirement of long-term dual antiplatelet therapy showed positive safety and short- and long-term clinical outcomes following treatment with OrbusNeich's Genous Stent, according to a study published online in EuroIntervention.

11 Jan 2011

Baylor Hamilton offers Arctic Front Cardiac CryoAblation Catheter system treatment for paroxysmal atrial fibrillation

Physicians at Baylor Jack and Jane Hamilton Heart and Vascular Hospital are the first in North Texas to offer the Arctic Front® Cardiac CryoAblation Catheter system, the first and only cryoballoon in the United States indicated to treat drug refractory recurrent symptomatic paroxysmal atrial fibrillation (PAF), a serious heart rhythm disorder that affects millions of Americans.

11 Jan 2011

Bioheart reports positive data from adipose derived stem cells study in critical limb ischemia

Bioheart, Inc. announced positive efficacy data has been reported from the registry study of bone marrow and adipose derived stem cells for the treatment of end stage critical limb ischemia with wounds. Vaclav Prochazka MD, PhD, MSc., of University Hospital Ostrava, Czech Republic presented data at the American Academy of Anti-Aging Medicine Conference in Las Vegas last month.

10 Jan 2011

Miracor’s PICSO System may help advance heart failure treatment

Miracor Medical Systems GmbH announced today that its PICSO® (Pressure-controlled Intermittent Coronary Sinus Occlusion) System, designed to improve outcomes for acute coronary syndrome (ACS) and heart failure patients, has been cited as a technology that "may advance heart failure (HF) treatment significantly".

10 Jan 2011

Critical Diagnostics' high sensitivity Presage ST2 Assay receives CE Mark approval

Critical Diagnostics announced today that it has received CE (Conformité Européenne) Mark for its high sensitivity Presage ST2 Assay and is commencing commercialization in Europe. The product is indicated for use as an aid in risk stratification of patients with heart failure or acute coronary syndrome. This regulatory milestone marks the first time that an assay has become commercially available for the clinical measurement of the biomarker soluble ST2.

7 Jan 2011

Research roundup: Accountable Care Organizations; Electronic health records; Medicaid and deficit reductions

Health Affairs: Accountable Care Organizations: Making Them Work - The January issue of the journal features several articles examining initiatives underway that could help form ACOs, such as Blue Cross Blue Shield of Massachusetts' "Alternative Quality Contract,"a modified global payment model in which annual payments to medical groups are linked to a per member per month budget.

7 Jan 2011

FDA approved KOMBIGLYZE XR for type 2 diabetes mellitus now available in pharmacies

Bristol-Myers Squibb Company, and AstraZeneca today announced that KOMBIGLYZE™ XR (saxagliptin and metformin HCl extended-release), approved by the U.S. Food and Drug Administration (FDA) on November 5, 2010, is now available by prescription in pharmacies across the United States.

7 Jan 2011

BG Medicine enters agreement to develop galectin-3 test for Siemens' automated immunoassay platforms

BG Medicine, Inc. announced today that it has entered into an agreement with Siemens Healthcare Diagnostics Inc., a division of Siemens Healthcare, one of the world's largest suppliers of clinical diagnostics to the healthcare industry, for the development and commercialization of a galectin-3 test for Siemens' automated immunoassay platforms for clinical laboratories.

7 Jan 2011

22.5% implanted defibrillators are unnecessary: Study

According to a new study nearly 20% of American patients who receive an implantable cardioverter-defibrillator (ICD) may not need it. These ICDs when unnecessary could put the patients at higher risk of death and serious complications than patients who meet the criteria for the life-saving device say authors of the study published in the Jan. 5 issue of the Journal of the American Medical Association.

6 Jan 2011

Metabolon announces publication of 'Metabolomic Distinction and Insights into the Pathogenesis of Human Primary Dilated Cardiomyopathy'

Metabolon, the leader in metabolomics, biomarker discovery and analysis, announces the publication of "Metabolomic Distinction and Insights into the Pathogenesis of Human Primary Dilated Cardiomyopathy", in the European Journal of Clinical Investigation.

6 Jan 2011

Medical experts issue warning about common practice of tablet splitting

Medical experts have issued a warning about the common practice of tablet splitting, after a study found that nearly a third of the split fragments deviated from recommended dosages by 15 per cent or more.

6 Jan 2011

FDA grants additional marketing exclusivity to INOMAX for pediatric BPD treatment

Ikaria, Inc. today announced that the U.S. Food and Drug Administration has granted INOMAX for inhalation an additional six months of marketing exclusivity, known as "pediatric exclusivity."

6 Jan 2011

Tablet splitting leads to inaccurate dosages

5 Jan 2011

Predictive value of plasma galectin-3 levels in heart failure patients: Study

BG Medicine, a life sciences company focused on the discovery, development, and commercialization of novel diagnostics, today announced the publication of a study exploring the predictive value of plasma galectin-3 levels in heart failure (HF) patients with reduced and preserved ejection fraction.

5 Jan 2011

20% of patients who received implantable cardioverter-defibrillators did not meet guidelines for receipt of ICD

A study that included more than 100,000 patients who received implantable cardioverter-defibrillators (ICDs) found that about 20 percent did not meet evidence-based guidelines for receipt of an ICD, and that these patients had a significantly higher risk of in-hospital death than individuals who met criteria for receiving an ICD, according to a study in the January 5 issue of JAMA.

5 Jan 2011

GLUMETZA tablets are now available to wholesalers and physicians

Santarus, and Depomed, today announced that supply of GLUMETZA® 500 mg to wholesalers and retailers has resumed. GLUMETZA is a once-daily, extended release formulation of metformin and is approved for use in adults with type 2 diabetes mellitus.

5 Jan 2011

New program may help reduce hospital readmission rates for high-risk seniors

SCAN Health Plan and Lakewood IPA have partnered with Dovetail Health in a program designed to reduce readmission rates for high-risk seniors following discharge from hospitals and skilled nursing facilities.

4 Jan 2011

Embryome Sciences announces $4M equity financing, changes name to ReCyte Therapeutics

BioTime, Inc. today announced a $4 million equity financing by its subsidiary, Embryome Sciences, Inc. Concurrent with the financing, Embryome Sciences will be renamed ReCyte Therapeutics, Inc. and will develop therapeutic products for cardiovascular and blood diseases. The new equity financing is being led by a $2.5 million investment by private investors and a $1.5 million investment from BioTime that valued ReCyte Therapeutics at a post money valuation of $60 million on a fully diluted basis.

4 Jan 2011

FDA authorizes Juventas' JVS-100 Phase II clinical trial for critical limb ischemia

Juventas Therapeutics, a clinical-stage regenerative medicine company developing novel therapies for cardiovascular disease, announces that the U.S. Food and Drug Administration (FDA) authorized commencement of a Phase II clinical trial evaluating the efficacy and safety of its lead product, JVS-100, for the treatment of critical limb ischemia (CLI).

3 Jan 2011

Heart Failure News and Research

Further Reading

Bioheart announces primary focus on completing clinical evaluation of cell therapies for heart failure

DAPT shows positive outcomes following treatment with OrbusNeich's Genous Stent

Baylor Hamilton offers Arctic Front Cardiac CryoAblation Catheter system treatment for paroxysmal atrial fibrillation

Bioheart reports positive data from adipose derived stem cells study in critical limb ischemia

Miracor’s PICSO System may help advance heart failure treatment

Critical Diagnostics' high sensitivity Presage ST2 Assay receives CE Mark approval

Research roundup: Accountable Care Organizations; Electronic health records; Medicaid and deficit reductions

FDA approved KOMBIGLYZE XR for type 2 diabetes mellitus now available in pharmacies

BG Medicine enters agreement to develop galectin-3 test for Siemens' automated immunoassay platforms

22.5% implanted defibrillators are unnecessary: Study

Metabolon announces publication of 'Metabolomic Distinction and Insights into the Pathogenesis of Human Primary Dilated Cardiomyopathy'

Medical experts issue warning about common practice of tablet splitting

FDA grants additional marketing exclusivity to INOMAX for pediatric BPD treatment

Tablet splitting leads to inaccurate dosages

Predictive value of plasma galectin-3 levels in heart failure patients: Study

20% of patients who received implantable cardioverter-defibrillators did not meet guidelines for receipt of ICD

GLUMETZA tablets are now available to wholesalers and physicians

New program may help reduce hospital readmission rates for high-risk seniors

Embryome Sciences announces $4M equity financing, changes name to ReCyte Therapeutics

FDA authorizes Juventas' JVS-100 Phase II clinical trial for critical limb ischemia

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News